The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
Market view
elbasvir and grazoprevir
2 marketed package NDCs · 2 active manufacturers
Same drug class
Other molecules FDA puts in Hepatitis C Virus NS3/4A Protease Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Elbasvir and grazoprevir in shortage right now?
- No. FDA does not currently list Elbasvir and grazoprevir in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Elbasvir and grazoprevir?
- 2 companies have marketed Elbasvir and grazoprevir in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
Shortage reports for this molecule
- Planned discontinuation — Zepatier, Tablet, 50 mg; 100 mg (NDC 0006-3074-02)Oct 17, 2025
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.